MAPT and Alzheimer disease: We also confirmed other previous AD EWAS associations, including a site annotated to ANK1 (cg05066959; P = 1.16E–13, effect size = 0.41%) that has been robustly associated with AD pathology in previous EWAS studies of AD11,15,16 and was characterized by elevated DNA methylation with increased tau pathology (Fig. 3b).